Literature DB >> 23348953

Foxp3+ regulatory T cells are activated in spite of B7-CD28 and CD40-CD40L blockade.

Isabel Vogel1, Bert Verbinnen, Wim Maes, Louis Boon, Stefaan W Van Gool, Jan L Ceuppens.   

Abstract

Costimulatory signals are required for priming and activation of naive T cells, while it is less clear how they contribute to induction of regulatory T (Treg)-cell activity. We previously reported that the blockade of the B7-CD28 and CD40L-CD40 interaction efficiently suppresses allogeneic T-cell activation in vivo. This was characterized by an initial rise in Foxp3(+) cells, followed by depletion of host-reactive T cells. To further investigate effects of costimulatory blockade on Treg cells, we used an in vitro model of allogeneic CD4(+) cell activation. When CTLA-4Ig and anti-CD40L mAb (MR1) were added to the cultures, T-cell proliferation and IL-2 production were strongly reduced. However, Foxp3(+) cells proliferated and acquired suppressive activity. They suppressed activation of syngeneic CD4(+) cells much more efficiently than did freshly isolated Treg cells. CD4(+) cells activated by allogeneic cells in the presence of MR1 and CTLA-4Ig were hyporesponsive on restimulation, but their response was restored to that of naive CD4(+) cells when Foxp3(+) Treg cells were removed. We conclude that natural Treg cells are less dependent on B7-CD28 or CD40-CD40L costimulation compared with Foxp3(-) T cells. Reduced costimulation therefore alters the balance between Teff and Treg-cell activation in favor of Treg-cell activity.
© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23348953     DOI: 10.1002/eji.201242737

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  12 in total

1.  Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma.

Authors:  Abhishek D Garg; Lien Vandenberk; Matthias Van Woensel; Jochen Belmans; Marco Schaaf; Louis Boon; Steven De Vleeschouwer; Patrizia Agostinis
Journal:  Oncoimmunology       Date:  2017-03-03       Impact factor: 8.110

2.  Hyperlipidemia Alters Regulatory T Cell Function and Promotes Resistance to Tolerance Induction Through Costimulatory Molecule Blockade.

Authors:  J Bagley; J Yuan; A Chandrakar; J Iacomini
Journal:  Am J Transplant       Date:  2015-06-16       Impact factor: 8.086

3.  The role of IL-6 in hyperlipidemia-induced accelerated rejection.

Authors:  Linus Williams; Jessamyn Bagley; John Iacomini
Journal:  Am J Transplant       Date:  2021-10-12       Impact factor: 8.086

4.  Intranasal administration of abatacept enhances IL-35+ and IL-10+ producing Bregs in lung tissues of ovalbumin-sensitized asthmatic mice model.

Authors:  Maha Fahad Alenazy; Fatemeh Saheb Sharif-Askari; Mohammed S El-Wetidy; Narjes Saheb Sharif-Askari; Ibrahim Yaseen Hachim; Mohammad-Hani Temsah; Basema Saddik; Roua Al-Kufaidy; Maha A Omair; Yasser A Alshawakir; Amany Adulgadel Fathaddin; Suad Hannawi; Qutayba Hamid; Mohammed A Omair; Saleh Al-Muhsen; Rabih Halwani
Journal:  PLoS One       Date:  2022-09-06       Impact factor: 3.752

5.  Abatacept Targets T Follicular Helper and Regulatory T Cells, Disrupting Molecular Pathways That Regulate Their Proliferation and Maintenance.

Authors:  Simon Glatigny; Barbara Höllbacher; Samantha J Motley; Cathy Tan; Christian Hundhausen; Jane H Buckner; Dawn Smilek; Samia J Khoury; Linna Ding; Tielin Qin; Jorge Pardo; Gerald T Nepom; Laurence A Turka; Kristina M Harris; Daniel J Campbell; Estelle Bettelli
Journal:  J Immunol       Date:  2019-01-25       Impact factor: 5.422

Review 6.  Differential sensitivity of regulatory and effector T cells to cell death: a prerequisite for transplant tolerance.

Authors:  Sylvaine You
Journal:  Front Immunol       Date:  2015-05-19       Impact factor: 7.561

7.  Abatacept improves whole-body insulin sensitivity in rheumatoid arthritis: an observational study.

Authors:  Francesco Ursini; Emilio Russo; Marta Letizia Hribal; Daniele Mauro; Francesca Savarino; Caterina Bruno; Cesare Tripolino; Mariangela Rubino; Saverio Naty; Rosa Daniela Grembiale
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

Review 8.  Translating Mechanism of Regulatory Action of Tolerogenic Dendritic Cells to Monitoring Endpoints in Clinical Trials.

Authors:  Jessica S Suwandi; Tatjana Nikolic; Bart O Roep
Journal:  Front Immunol       Date:  2017-11-22       Impact factor: 7.561

9.  IL-2-Mediated In Vivo Expansion of Regulatory T Cells Combined with CD154-CD40 Co-Stimulation Blockade but Not CTLA-4 Ig Prolongs Allograft Survival in Naive and Sensitized Mice.

Authors:  Lerisa Govender; Jean-Christophe Wyss; Rajesh Kumar; Manuel Pascual; Dela Golshayan
Journal:  Front Immunol       Date:  2017-04-21       Impact factor: 7.561

10.  Platelet-cytokine Complex Suppresses Tumour Growth by Exploiting Intratumoural Thrombin-dependent Platelet Aggregation.

Authors:  Yu-Tung Li; Tomoyuki Nishikawa; Yasufumi Kaneda
Journal:  Sci Rep       Date:  2016-04-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.